BioFactura Receives $7.8 Million in Funding for Contract Options for its Smallpox Biodefense Therapeutic
Frederick, Maryland, November 5, 2024: BioFactura, Inc. recently announced contract option activations totaling $7.8 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract valued at up to $78 million for … Continue reading